FDA Rejection Pushes Incyte Stock Sharply Lower

The security is trading at its lowest level since October

Digital Content Manager
Mar 24, 2023 at 11:05 AM
facebook X logo linkedin

The shares of Incyte Corporation (NASDAQ:INCY) are down 5.3% at $68.33 at last check, after the U.S. Food and Drug Administration (FDA) failed to approve the extended-release version of the company's cancer drug Jakafi, which will lose market exclusivity in 2028. 

The shares are trading at their lowest level since October, and eyeing their worst single-day percentage drop since August 2022. The security now carries a 14.7% year-to-date deficit, and has breached a recent floor at the $72 region. Meanwhile, the 20-day moving average has been acting as pressure since early February. 

The options pits lean overwhelmingly bearish, per INCY's 50-day call/put volume ratio of 1.52 over at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which sits higher than all readings from the past year. 

Options look like a solid way to bet on Incyte stock's next moves. This is per the equity's Schaeffer's Volatility Index (SVI) of 24% that sits higher than just 14% of annual readings.



How to collect 1 dividend check every day for LIFE

Did you know you could collect 1 dividend check every day the market is open? You could also do it starting with just $605! For me, I'm collecting 70 dividend checks every quarter…which averages around 1.1 dividend checks every business day. There's no trading behind this... no penny stocks or high-risk investments. All you do is buy and hold and you're set. There's no set up required either. If you start buying the dividend stocks I show you today... you could collect 1 dividend per day starting as early as this week. Click here for all the details.